Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
You must be a Standard 1 Year member to access this content.
Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Castlight Health on the deal, while Kirkland & Ellis advised Vera Whole Health. Castlight Health (NYSE: CSLT), a leading healthcare data and...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised DICE Therapeutics on the deal. DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of...
You must be a Standard 1 Year member to access this content.
Shearman & Sterling advised Leeward Renewable Energy Operations, while Latham & Watkins represented the initial purchasers in the offering. Leeward Renewable Energy Operations, a wholly owned...
You must be a Standard 1 Year member to access this content.
